Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab

Dermatol Ther. 2018 Nov;31(6):e12671. doi: 10.1111/dth.12671. Epub 2018 Sep 24.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Autoantibodies / blood*
  • Autoantibodies / immunology
  • Autoimmunity / drug effects*
  • Biomarkers / blood
  • Desmoglein 1 / immunology*
  • Drug Administration Schedule
  • Drug Monitoring / methods
  • Female
  • Glucocorticoids / administration & dosage*
  • Glucocorticoids / adverse effects
  • Humans
  • Immunologic Factors / administration & dosage*
  • Immunologic Factors / adverse effects
  • Male
  • Middle Aged
  • Pemphigus / blood
  • Pemphigus / diagnosis
  • Pemphigus / drug therapy*
  • Pemphigus / immunology
  • Predictive Value of Tests
  • Prednisolone / administration & dosage*
  • Prednisolone / adverse effects
  • Retrospective Studies
  • Rituximab / administration & dosage*
  • Rituximab / adverse effects
  • Treatment Outcome
  • Young Adult

Substances

  • Autoantibodies
  • Biomarkers
  • DSG1 protein, human
  • Desmoglein 1
  • Glucocorticoids
  • Immunologic Factors
  • Rituximab
  • Prednisolone